Compare UG & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UG | NRSN |
|---|---|---|
| Founded | 1942 | 2017 |
| Country | United States | Israel |
| Employees | N/A | 16 |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.8M | 26.5M |
| IPO Year | 1995 | N/A |
| Metric | UG | NRSN |
|---|---|---|
| Price | $7.00 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 5.7K | ★ 143.3K |
| Earning Date | 05-11-2026 | 03-31-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $10,545,468.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | $35.85 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.58 | $0.63 |
| 52 Week High | $9.88 | $2.60 |
| Indicator | UG | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 53.78 | 51.83 |
| Support Level | $6.31 | $0.67 |
| Resistance Level | $7.70 | $0.86 |
| Average True Range (ATR) | 0.30 | 0.06 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 43.59 | 35.02 |
United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.